NDA 22267, held by Abbvie Inc. Divalproex Sodium.
As of Nov 13, 2026, NDA 22267 (Depakote Er), held by Abbvie Inc, was first approved by FDA on Mar 24, 2008, with 1 approved supplement and 0 published complete response letters.
| Oct 15, 2009 | Supplement 1Efficacy (new indication or use) · Standard review | Approved | |
| Mar 24, 2008 | Original applicationTYPE 6 · Priority review | Approved |
| Depakote Er250MG · tablet, extended release; oral | Divalproex Sodium | Rx |
| Depakote Er500MG · tablet, extended release; oral | Divalproex Sodium | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
